RANTES augments eosinophil lucigenin-dependent chemiluminescence.
BACKGROUND
RANTES (regulated on activation, normal T expressed and secreted) has been shown to possess chemotactic activity for eosinophils. Eosinophils have been considered to play a key role in the allergic inflammation through the release of inflammatory molecules such as radical oxygen products. Thus, in this study, we examined the effect of RANTES on radical oxygen products from eosinophils.


METHODS
Eosinophils were isolated from heparinized venous blood of patients with bronchial asthma by the modified CD16-negative depletion method. Radical oxygen products were examined in terms of lucigenin-dependent chemiluminescence. To a mixture of 50 microl of eosinophils (2x10(6)/ml) and 50 microl of lucigenin (5x10(-4)M), 50 microl of calcium ionophore A23187 (final concentration 10(-5)M) was added, and radical oxygen products were determined for 600 s.


RESULTS
RANTES treatment resulted in the enhancement of peak value (0.64+/-0.23 RLU) and integrated value (119.08+/-20.52 RLU) as compared to untreated cells (0.15+/-0.03 RLU, 29.48+/-8.92 RLU, respectively). CONCLUSIONS We could conclude that RANTES might play an important role in the pathogenesis of allergic inflammation through involvement in selective eosinophil infiltration and eosinophil activation by augmentation of eosinophil oxidative metabolism.
Department of Clinical and Laboratory Medicine, Akita University School of Medicine, Hondo, Akita, Japan.
J
J
Chihara
T
T
Kakazu
I
I
Higashimoto
N
N
Saito
K
K
Honda
A
A
Tsuda
H
H
Kayaba
Y
Y
Kamada
H
H
Oyamada
O
O
Urayama
D000166:Acridines; D001249:Asthma / Q000209:etiology / Q000276:immunology; D000001:Calcimycin / Q000494:pharmacology; D018946:Chemokine CCL5 / Q000494:pharmacology* / Q000502:physiology; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007249:Inflammation / Q000209:etiology / Q000276:immunology; D018836:Inflammation Mediators / Q000502:physiology; D007476:Ionophores / Q000494:pharmacology; D008163:Luminescent Measurements; D017382:Reactive Oxygen Species / Q000378:metabolism*
D000166:Acridines; D018946:Chemokine CCL5; D005609:Free Radicals; D018836:Inflammation Mediators; D007476:Ionophores; D017382:Reactive Oxygen Species; C033472:10,10'-dimethyl-9,9'-biacridinium; D000001:Calcimycin